打开APP

BioAlliance继续推进抗癌药Livatag III期肝癌研究

  1. BioAlliance
  2. Livatag
  3. 肝癌

来源:生物谷 2014-04-17 09:05

数据安全监测委员会一致建议BioAlliance继续推进抗癌药Livatag III期肝癌研究。

2012年4月17日讯 /生物谷BIOON/ --专注于孤儿药研发的BioAlliance制药4月15日宣布,负责ReLive III其试验的数据安全和监测委员会(DSMB)欧洲独立专家委员会已举行第4次会议,再次一致建议继续推进该项研究而无需修改试验方案。DSMB每6个月召开一次会议,评估Livatag(doxorubicin nanoparticle,阿霉素纳米颗粒)的耐受性并确保患者安全。

ReLive是一项国际性、随机III其临床试验,旨在证明Livatag用于既往经安进(Amgen)和拜耳(Bayer)多吉美(Nexavar,通用名:sorafenib,索拉非尼)治疗失败或不耐受的400例晚期肝癌(原发性肝癌)患者的生存疗效。该公司预计,若最终获批,Livatag的年销售潜力将达到8亿欧(约合11亿美元)。(生物谷Bioon.com)

英文原文:BioAlliance Pharma to continue Phase III trial of Livatag in liver cancer

Orphan disease specialist BioAlliance Pharma (Euronext Paris: BIO) says that the European Independent Board of Experts (Data Safety and Monitoring Board, DSMB), in charge of the safety profile of the ReLive Phase III trial, has unanimously recommended continuing the study without modification.

The DSMB meets every six months to evaluate the tolerance of Livatag (doxorubicin transdrug) and to ensure patient safety. For the fourth time since November 2012, the DSMB unanimously recommended to continue the study without modification, based on its positive assessment of all safety data of Livatag and confirmed the good safety profile of the product.

Sales potential of $1 billion

ReLive is an international, randomized Phase III trial aiming at demonstrating the efficacy of Livatag on survival in 400 patients with advanced hepatocellular carcinoma (primary liver cancer) after failure or intolerance to Nexavar (sorafenib) from US biotech firm Amgen (Nasdaq: AMGN) and partner German pharma major Bayer (BAYN: DE). The trial is still expanding in Europe and implementation of investigator centers is ongoing in the USA further to the green light obtained from the US Food and Drug Administration in December. The recruitment should be completed by the end of 2015 for expected data end of 2016.

Judith Greciet, chief executive of BioAlliance Pharma, said: “Each new positive recommendation from our DSMB - now covering over 25% of enrolled patients - strengthens the tolerance evaluation of Livatag. This positive evaluation is a major step forward in the overall assessment of this drug being developed for a rare cancer with no or few therapeutic alternatives, and representing sales potential estimated at nearly 800 million euros ($1.1 billion).”

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->